Get the Stockscreener App
52.96
1.38%
-0.74
Royalty Pharma Plc stock is traded at $52.96, with a volume of 8.57M.
It is down -1.38% in the last 24 hours and up +1.71% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$53.70
Open:
$54.38
24h Volume:
8.57M
Relative Volume:
2.39
Market Cap:
$23.48B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
27.74
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
-4.21%
1M Performance:
+1.71%
6M Performance:
+37.81%
1Y Performance:
+51.70%
1-Day Range:
$51.15
$54.38
1-Week Range:
$51.15
$56.00
52-Week Range:
$34.08
$56.50
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
52.96 | 23.48B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dorsey Asset Management LLC Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Delta Global Management LP Acquires Shares of 44,314 Royalty Pharma PLC $RPRX - MarketBeat
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report - Stock Titan
L2 Asset Management LLC Has $5.63 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 31,091 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Bought by Entropy Technologies LP - MarketBeat
Fieldview Capital Management LLC Invests $3.74 Million in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Raises Stake in Royalty Pharma PLC $RPRX - MarketBeat
Rhenman & Partners Asset Management AB Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
This Royalty Pharma Insider Reduced Their Stake By 10% - Yahoo Finance
Heartland Advisors Inc. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
TD Asset Management Inc Has $9.19 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
CenterBook Partners LP Has $2.71 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04 - marketscreener.com
RPRX: Synthetic royalties and R&D partnerships drive growth, with China and large pharma as key opportunities - TradingView
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
RPRX Q1 2026 Earnings: EPS Surpasses Estimates by 5.11%, Stock SlipsEarnings Stability Report - newsline.com
Royalty Pharma (RPRX) director receives 4,545 share unit award - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant - Stock Titan
Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX) - Stock Titan
Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant - Stock Titan
Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares - Stock Titan
Royalty Pharma (RPRX) awards 4,545 RSUs to board director - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan - Stock Titan
Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighTime to Buy? - MarketBeat
Royalty Pharma (RPRX) Stock Analysis: Is the 6.05% Potential Upside Worth the Investment? - DirectorsTalk Interviews
Capital International Inc. CA Acquires 58,030 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Increased by Brandywine Global Investment Management LLC - MarketBeat
Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026 - marketscreener.com
Los Angeles Capital Management LLC Purchases 212,294 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Capital International Ltd. CA - MarketBeat
Capital International Sarl Purchases 166,334 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Investors - MarketBeat
Capital Group Investment Management PTE. LTD. Has $2.53 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Cash from operating activities of Royalty Pharma Plc Class A – XETR:RPD - TradingView
Operating expenses (excl. COGS) of Royalty Pharma Plc Class A – XETR:RPD - TradingView
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):